Riskpilot← Back to searchSign inGet full accessLexona AB
ABActiveOrg 5565458147Kalendegatan 18Legal activities · NACE 6910Est. 19975 employees
Revenue 2025
SEK 2,5M
-15% vs 2024
EBITDA margin
-22.9%
-247% vs 2024
Equity ratio
51.7%
Financial strength
Net profit 2025
SEK -214K
-168% vs 2024
| Revenue | SEK 2,5M | -15% |
| EBITDA | SEK -562K | -247% |
| Net profit | SEK -214K | -168% |
| Total assets | SEK 2,4M | -8% |
| Equity | SEK 1,2M | -15% |
| Employees | 5 | — |
Legal name
Lexona AB
Org number
5565458147
Legal form
Aktiebolag
NACE code
6910 · Legal activities
Founded
21 oktober 1997
Share capital
SEK 100 000
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva juridisk byrå och därmed förknippad verksamhet.
Address
Kalendegatan 18
Phone
+4640121501
Email
info@lexona.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 667 | 1 108 | 1 808 | 2 884 | 2 456 |
| Staff expenses | — | −219 | — | −1 903 | −1 914 |
| EBITDA | 276 | 444 | 902 | 383 | −562 |
| Depreciation & amort. | −0 | — | −0 | — | — |
| EBIT | 276 | 444 | 902 | 383 | −562 |
| Net financials | −1 | −1 | 6 | 18 | 8 |
| Profit before tax | 276 | 330 | 681 | 401 | −214 |
| Tax | −60 | −70 | −145 | −87 | — |
| Net profit | 216 | 260 | 536 | 314 | −214 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 520 | 923 | 1 776 | 2 580 | 2 384 |
| Equity | 336 | 596 | 1 132 | 1 446 | 1 232 |
| Long-term debt | 0 | — | 0 | — | — |
| Short-term debt | 184 | 214 | 303 | 794 | 1 152 |
| Total debt | 184 | 214 | 303 | 794 | 1 152 |
EBITDA margin
-22.9%
This company
15.8%
Market median
-245% vs market
20212025
Equity ratio
51.7%
This company
38.2%
Market median
+35% vs market
20212025
Return on equity
-17.4%
This company
18.4%
Market median
-195% vs market
20212025
Net profit margin
-8.7%
This company
8.1%
Market median
-207% vs market
20212025
Asset turnover
1.03×
This company
1.12×
Market median
+8% vs market
20212025
Debt / equity
0.94×
This company
0.62×
Market median
+52% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
RL Chief Executive Officer | Chief Executive Officer | 2021 |
AM Chief Auditor | Chief Auditor | 2022 |
| Former (1) | ||
ET | Audit | 2020 – 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2024 | |
| Former (2) | ||
| Deputy Board Member | 2020 – 2021 | |
| Deputy Board Member | 2021 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Lexona AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Robin Lars Stig Spaak | Chief Executive Officer | 0 companies |
| Erik Torsten Helge Wänström | Audit | 0 companies |
| Annika Maria Jönsson | Chief Auditor | 0 companies |
| Lena Elisabeth Norberg Spaak | Deputy Board Member | 0 companies |
| Sara Spaak | Deputy Board Member | 0 companies |
| Rolf Spaak | Deputy Board Member | 0 companies |